# Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

> **NCT04945772** · PHASE2 · COMPLETED · sponsor: **Nanoscope Therapeutics Inc.** · enrollment: 27 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Retinitis
- Retinal Diseases
- Eye Diseases
- Eye Diseases, Hereditary
- Retinal Dystrophies
- Retinal Degeneration

## Interventions

- **BIOLOGICAL:** Gene Therapy Product-MCO-010
- **PROCEDURE:** Sham Injection

## Key facts

- **NCT ID:** NCT04945772
- **Lead sponsor:** Nanoscope Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-13
- **Primary completion:** 2023-02-27
- **Final completion:** 2024-01-18
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04945772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04945772, "Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04945772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*